Elos Medtech Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Elos Medtech heeft een totaal eigen vermogen van SEK788.2M en een totale schuld van SEK407.1M, wat de schuld-eigenvermogensverhouding op 51.6% brengt. De totale activa en totale passiva bedragen respectievelijk SEK1.6B en SEK772.0M. De EBIT Elos Medtech is SEK136.9M waardoor de rentedekking 3.2 is. Het heeft contanten en kortetermijnbeleggingen van SEK117.3M.

Belangrijke informatie

51.6%

Verhouding schuld/eigen vermogen

SEK 407.10m

Schuld

Rente dekkingsratio	3.2x
Contant	SEK 117.30m
Aandelen	SEK 788.20m
Totaal verplichtingen	SEK 772.00m
Totaal activa	SEK 1.56b

Recente financiële gezondheidsupdates

We Think Elos Medtech (STO:ELOS B) Is Taking Some Risk With Its Debt

Mar 24

Elos Medtech (STO:ELOS B) Has A Somewhat Strained Balance Sheet

Dec 13

Recent updates

The President & CEO of Elos Medtech AB (publ) (STO:ELOS B), Jan Wahlström, Just Bought 28% More Shares

Feb 28

Do Fundamentals Have Any Role To Play In Driving Elos Medtech AB (publ)'s (STO:ELOS B) Stock Up Recently?

Feb 24

Elos Medtech (STO:ELOS B) Has Gifted Shareholders With A Fantastic 102% Total Return On Their Investment

Feb 11

When Should You Buy Elos Medtech AB (publ) (STO:ELOS B)?

Jan 31

How Much Are Elos Medtech AB (publ) (STO:ELOS B) Insiders Taking Off The Table?

Jan 18

Returns On Capital At Elos Medtech (STO:ELOS B) Paint An Interesting Picture

Jan 06

Could The Elos Medtech AB (publ) (STO:ELOS B) Ownership Structure Tell Us Something Useful?

Dec 26

Elos Medtech (STO:ELOS B) Has A Somewhat Strained Balance Sheet

Dec 13

Here's Why We Don't Think Elos Medtech's (STO:ELOS B) Statutory Earnings Reflect Its Underlying Earnings Potential

Nov 30

Elos Medtech AB (publ)'s (STO:ELOS B) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Nov 17

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK577.9M ) ELOS B } overtreffen de korte termijn passiva ( SEK289.8M ).

Langlopende schulden: De kortetermijnactiva ELOS B ( SEK577.9M ) overtreffen de langetermijnschulden ( SEK482.2M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 36.8% ) ELOS B wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van ELOS B is de afgelopen 5 jaar gedaald van 57.1% naar 51.6%.

Schuldendekking: De schuld van ELOS B wordt goed gedekt door de operationele kasstroom ( 23.4% ).

Rentedekking: De rentebetalingen op de schuld van ELOS B worden goed gedekt door EBIT ( 3.2 x dekking).

Elos Medtech Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Nasdaq Stockholm Approves Elos Medtech's Application for De-Listing

Elos Medtech Applies for De-Listing from Nasdaq Stockholm

We Think Elos Medtech (STO:ELOS B) Is Taking Some Risk With Its Debt

Elos Medtech (STO:ELOS B) Has A Somewhat Strained Balance Sheet

Recent updates

Elos Medtech AB (publ) (OM:ELOS B) acquired Klingel Holding GmbH from IK Partners and Management.

Nasdaq Stockholm Approves Elos Medtech's Application for De-Listing

Elos Medtech Applies for De-Listing from Nasdaq Stockholm

New major risk - Shareholder dilution

Elos Medtech AB (publ) to Report Fiscal Year 2024 Results on Feb 28, 2025

Third quarter 2023 earnings released

Elos Medtech AB (publ) (OM:ELOS B) entered an agreement to acquire KLINGEL medical metal GmbH from IK Partners and Management for an enterprise value of €370 million.

New minor risk - Profit margin trend

Second quarter 2023 earnings released

Investor sentiment improves as stock rises 20%

Elos Medtech AB (Publ) Elects Winfried Schaller as Board Member

First quarter 2023 earnings released

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: kr9.31 (vs kr9.37 in FY 2021)

No independent directors

Elos Medtech AB (publ) to Report Q3, 2023 Results on Oct 19, 2023

Third quarter 2022 earnings released

Elos Medtech AB Announces Nomination Committee Appointments

Elos Medtech AB (Publ) Announces Management Changes

Elos Medtech AB (Publ) Announces Management Changes

Second quarter 2022 earnings released

Elos Medtech AB (publ) Omits Dividend for the Year 2021

First quarter 2022 earnings: Revenues miss analyst expectations

Less than half of directors are independent

Elos Medtech AB (publ)(OM:ELOS B) dropped from OMX Nordic Small Cap Index

Chief Financial Officer recently sold kr159k worth of stock

Chief Financial Officer recently sold kr159k worth of stock

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Elos Medtech AB (publ) (STO:ELOS B)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Independent Director recently sold kr848k worth of stock

Second quarter 2021 earnings released: EPS kr2.28 (vs kr0.85 in 2Q 2020)

TA Associates Management, L.P. through its funds Ta Xiii-B, L.P., Ta Xiii-A, L.P. and TA Investors XIII, L.P. made an offer to acquire Elos Medtech AB (publ) (OM:ELOS B) from a group of sellers for SEK 1.7 billion.

Elos Medtech in Talks of Possible Takeover Bid

Is Now The Time To Look At Buying Elos Medtech AB (publ) (STO:ELOS B)?

Here's Why I Think Elos Medtech (STO:ELOS B) Is An Interesting Stock

First quarter 2021 earnings released

Upcoming dividend of kr1.50 per share

Returns On Capital Are Showing Encouraging Signs At Elos Medtech (STO:ELOS B)

We Think Elos Medtech (STO:ELOS B) Is Taking Some Risk With Its Debt

President & CEO recently sold kr801k worth of stock

Should Elos Medtech AB (publ) (STO:ELOS B) Be Part Of Your Dividend Portfolio?

New 90-day high: kr121

The President & CEO of Elos Medtech AB (publ) (STO:ELOS B), Jan Wahlström, Just Bought 28% More Shares

President & CEO recently bought kr233k worth of stock

Revenue and earnings miss expectations

Full year 2020 earnings released: EPS kr4.46 (vs kr4.77 in FY 2019)

Do Fundamentals Have Any Role To Play In Driving Elos Medtech AB (publ)'s (STO:ELOS B) Stock Up Recently?

Elos Medtech (STO:ELOS B) Has Gifted Shareholders With A Fantastic 102% Total Return On Their Investment

New 90-day high: kr117

When Should You Buy Elos Medtech AB (publ) (STO:ELOS B)?

How Much Are Elos Medtech AB (publ) (STO:ELOS B) Insiders Taking Off The Table?

Elos Medtech AB (publ) Announces Executive Changes

Returns On Capital At Elos Medtech (STO:ELOS B) Paint An Interesting Picture

New 90-day high: kr109

Could The Elos Medtech AB (publ) (STO:ELOS B) Ownership Structure Tell Us Something Useful?

Elos Medtech (STO:ELOS B) Has A Somewhat Strained Balance Sheet

Here's Why We Don't Think Elos Medtech's (STO:ELOS B) Statutory Earnings Reflect Its Underlying Earnings Potential

Elos Medtech AB (publ)'s (STO:ELOS B) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

New 90-day high: kr98.80

Third-quarter earnings released: Revenue and earnings beat expectations

Third quarter earnings released

Elos Medtech AB (publ) to Report Q3, 2021 Results on Oct 20, 2021

New 90-day high - kr89.60

New 90-day high - kr77.20

Analyse van de financiële positie